Investigating the role of ALS genes CHCHD10 and TUBA4A in Belgian FTD-ALS spectrum patients

Abstract: Mutation screening and phenotypic profiling of 2 amyotrophic lateral sclerosis(ALS) and frontotemporal dementia(FTD) associated genes, CHCHD10 and TUBA4A, were performed in a Belgian cohort of 459 FTD, 28 FTD-ALS, and 429 ALS patients. In CHCHD10, we identified a novel nonsense mutation (p.Gln108*) in a patient with atypical clinical FTD and pathology-confirmed Parkinson's disease (1/459, 0.22%) leading to loss of transcript. We further observed 3 previously described missense variants (p.Pro34Ser, p.Pro80Leu, and p.Pro96Thr) that were also present in the matched control series. In T... Mehr ...

Verfasser: Perrone, Federica
Nguyen Phuoc, Hung
Van Mossevelde, Sara
Moisse, Matthieu
Sieben, Anne
Santens, Patrick
De Bleecker, Jan
Vandenbulcke, Mathieu
Engelborghs, Sebastiaan
Baets, Jonathan
Cras, Patrick
Vandenberghe, Rik
De Jonghe, Peter
De Deyn, Peter Paul
Martin, Jean-Jacques
Van Damme, Philip
Van Broeckhoven, Christine
van der Zee, Julie
Dokumenttyp: acceptedVersion
Erscheinungsdatum: 2017
Schlagwörter: Biology / Human medicine
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-26915951
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://hdl.handle.net/10067/1406380151162165141

Abstract: Mutation screening and phenotypic profiling of 2 amyotrophic lateral sclerosis(ALS) and frontotemporal dementia(FTD) associated genes, CHCHD10 and TUBA4A, were performed in a Belgian cohort of 459 FTD, 28 FTD-ALS, and 429 ALS patients. In CHCHD10, we identified a novel nonsense mutation (p.Gln108*) in a patient with atypical clinical FTD and pathology-confirmed Parkinson's disease (1/459, 0.22%) leading to loss of transcript. We further observed 3 previously described missense variants (p.Pro34Ser, p.Pro80Leu, and p.Pro96Thr) that were also present in the matched control series. In TUBA4A, we detected a novel frameshift mutation (p.Arg64Glyfs*90) leading to a truncated protein in 1 FTD patient (1/459 of 0.22%) with family history of Parkinson's disease and cognitive impairment, and a novel missense mutation (p.Thr381Met) in 2 sibs with familial ALS and memory problems (1 index patient/429, 0.23%) in whom we previously identified a pathogenic Chromosome 9 open reading frame 72 repeat expansion mutation. The present study confirms the role of CHCHD10 and TUBA4A in the FTD-ALS spectrum, although genetic variations in these 2 genes are extremely rare in the Belgian population and often associated with symptomatology of related neurodegenerative diseases including Parkinson's disease and Alzheimer's disease.